FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL						
OMB Number: 3235-0						
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  KANZER STEVE H				- 1	2. Issuer Name and Ticker or Trading Symbol  Synthetic Biologics, Inc. [ SYN ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
(Last)	(F	First)	(Middle)		- 1	3. Date of Earliest Transaction (Month/Day/Year) 04/28/2014								Director X 10% Owner  Officer (give title X Other (specify below)  Prior Director						
C/O PHARMAINVESTORS LLC 9045 LA FONTANA BLVD., STE. 238				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)							·) 6. Ir	6. Individual or Joint/Group Filing (Check Applicable							
(Street) BOCA RATON FL 33434					Line)  X Form filed by One Reporting Per  Form filed by More than One Re  Person										erson	n				
(City)	2)	State)	(Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date			2. Transad Date (Month/D		Year) Exe		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Follo		6. Owne Form: Di (D) or In (I) (Instr		Indire Benet Owne	Nature of direct neficial vnership		
									V	Amount	(A) or (D)	Price	Reported Transaction( (Instr. 3 and				(Instr. 4)			
Commo	n Stock													375,24	16	D	)			
Common Stock			04/28/2014		14 04/28/2014		S		175,177	7 D	\$2.86(1)	6,911,203		<b> </b> (2)		Ven	Accredited Venture Capital LLC			
Common Stock			04/29	/2014	:014 0		04/29/2014			87,935	D	\$2.98(1)	6,823,268		<b>[</b> (2)		Accredited Venture Capital LLC			
			Tab						-	-	posed of,		-	vned						
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Executive or Exercise (Month/Day/Year) any			ned	4. Transac	ansaction Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.3, 4 and 5)		vative rities uired rosed	nts, options, convertible  6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	deriva Securi Benefi Owned Follow Repor	rities Form ficially Direct ed or In wing (I) (Ir orted saction(s)		ship D) rect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisable		xpiration Date	Title	Amount o Number of Shares	r						
Stock Options	\$2.01								10/31/200	6 0	5/27/2014	Common	271,058	3	271	,058	D			
Stock Options	\$0.74							1	12/01/201	0 0	5/27/2014	Common	8,333		8,3	8,333 D		$\neg$		
Stock Options	\$1.5								01/05/201	1 0	5/27/2014	Common	25,000		25,000		D			

## Explanation of Responses:

- 1. Represents weighted average price per share for the total number of shares sold on such day.
- 2. Mr. Kanzer is the managing member of Pharmainvestors LLC, the managing member of Accredited Venture Capital LLC.

<u>/s/ Steve H. Kanzer</u>

04/30/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.